Haby A Henary
Overview
Explore the profile of Haby A Henary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moschos S, Sandhu S, Lewis K, Sullivan R, Puzanov I, Johnson D, et al.
Invest New Drugs
. 2022 May;
40(5):1051-1065.
PMID: 35635631
Background: Targeting the MDM2-p53 interaction using AMG 232 is synergistic with MAPK inhibitors (MAPKi) in preclinical melanoma models. We postulated that AMG 232 plus MAPKi is safe and more effective...
2.
Gluck W, Gounder M, Frank R, Eskens F, Blay J, Cassier P, et al.
Invest New Drugs
. 2019 Jul;
38(3):831-843.
PMID: 31359240
Background This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In...
3.
Erba H, Becker P, Shami P, Grunwald M, Flesher D, Zhu M, et al.
Blood Adv
. 2019 Jun;
3(13):1939-1949.
PMID: 31253596
This open-label, phase 1 study evaluated the safety, pharmacokinetics, and maximum tolerated dose of AMG 232, an investigational oral, selective mouse double minute 2 homolog inhibitor in relapsed/refractory acute myeloid...
4.
Rosenthal M, Curry R, Reardon D, Rasmussen E, Upreti V, Damore M, et al.
Cancer Chemother Pharmacol
. 2019 Jun;
84(2):327-336.
PMID: 31154523
Purpose: Epidermal growth factor receptor variant III (EGFRvIII) is expressed in a significant percentage of primary and recurrent glioblastoma (GBM), a common malignant primary brain tumor in adults. AMG 595...